Celon Pharma (WAR:CLN) Cash-to-Debt : 7.21 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Celon Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Celon Pharma's cash to debt ratio for the quarter that ended in Sep. 2024 was 7.21.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Celon Pharma could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Celon Pharma's Cash-to-Debt or its related term are showing as below:

WAR:CLN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.24 Med: 12.62 Max: No Debt
Current: 7.21

During the past 9 years, Celon Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.24. And the median was 12.62.

WAR:CLN's Cash-to-Debt is ranked better than
72.61% of 1004 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs WAR:CLN: 7.21

Celon Pharma Cash-to-Debt Historical Data

The historical data trend for Celon Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Celon Pharma Cash-to-Debt Chart

Celon Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

40.18

1.73

15.25

6.14

4.48

Celon Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															6.14	4.48	4.47	7.94	7.21

Competitive Comparison of Celon Pharma's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celon Pharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Celon Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Celon Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	114.543	/	(19.88	+	5.71)
	=	4.48

Celon Pharma's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	103.282	/	(7.127	+	7.198)
	=	7.21

Celon Pharma (WAR:CLN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Celon Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Celon Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (WAR:CLN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

8RP:Germany

Address

Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website

http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines